Zilico’s pioneering hand held product, the APX, offers cervical cancer results in real time, removing several weeks of waiting.
The ground breaking technology will be on display at MEDICA - the largest medical technologies fair in the world, where the company is seeking worldwide sales and marketing partners for its first application.
The APX is a portable hand-held device that measures the resistivity of cells and detects any changes as they progress from normal through to cancerous.
Cervical cancer affects around 500,000 women worldwide each year and is responsible for 300,000 deaths annually, so its ability to provide objective and accurate results in ‘real-time’ means it will offer a quicker diagnosis for both patients and clinicians worldwide.
It will help to better manage the disease and also significantly reduce morbidity from over-treatment due to false positives and under-treatment due to false negative smears. The system is safe and painless and has two functionalities within the one unit - the APX 100, which supports clinicians within their diagnostic procedure and the APX 200, which is a point of care (POC) test.
The APX100 enables colposcopists to better target biopsy sites helping to reduce the number of diagnostic biopsies and avoid the gross over-treatment of mild abnormalities. It has undergone four separate clinical trials and is currently in the middle of an EU multi-centre trial. Once this is completed, it will be launched across the European Union in H1 2011.
Recent figures showing a worrying reduction in the amount of women taking cervical cancer testing, could be set to improve thanks to a pioneering UK product that is faster and more accurate - delivering life saving results instantly.
In the UK alone figures show a drop in screening numbers by over
354, 000 over the last year – a disturbing trend for a potentially fatal disease that kills around three women in the UK daily.
The APX 200 application is being targeted at the cervical screening market as it provides a real-time diagnosis at the primary point-of-care thus reducing the significant traffic in the healthcare system between primary care, cytology laboratories and colposcopy clinics. Ultimately it will result in a more effective application of limited healthcare resources.
Sameer Kothari, Chief Executive of Zilico Limited, said: “The APX 100 will significantly improve the diagnosis of women who have been referred after an abnormal smear. It will also help establish the use of a bioimpedance device within the cervical cancer pathway.”
MEDICA is the largest medical technologies fair in the world and will be taking place between 17-20 November at the Messe Düsseldorf. Throughout the show Zilico will be located on the UK Pavilion, hall 16 stand G10.
Zilico are also in the process of developing an oral cancer application; to allow dentists to analyse whether common red and white lesions are cancerous in real time rather than sending patients for a biopsy.
For more information visit www.zilico.co.uk